ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: A study in 36 patients

Piercarlo Saletti, Emanuele Zucca, Melanie Gueneau, Fedro Peccatori, Franco Cavalli, Giovanni Martinelli

Research output: Contribution to journalArticlepeer-review


Prolonged remission can now be induced in the majority of patients with advanced Hodgkin's disease (HD) by the use of non-cross-resistant regimens. The aim of this retrospective analysis was to evaluate the efficacy and tolerability of a hybrid chemotherapy regimen (ChlVPP/ABV-VP16) in this unfavorable subset of patients. From 1982 to 1997 thirty-six previously untreated patients with advanced HD, Stages IIB to IV according to the Ann Arbor classification, were treated with the ChlVPP/ABV-VP16 regimen. The median age of the group was 29 years (range, 18 to 74), and 50% of them had bulky disease. Complete remission (CR) was induced in 31 patients (86%); 3 patients achieved partial responses and 2 had progressive disease. The median follow-up duration is 5.7 years, with a 5-year overall survival rate of 80%. At 5 years, the time to progression (TTP) and event-free survival (EFS) were 71% and 64%, respectively. Acute toxicity was quite acceptable, and there were no treatment-related deaths. A total of 3 second malignancies (8%) were documented. In conclusion, the ChlVPP/ABV-VP16 hybrid is an active regimen for use in advanced HD. Its overall survival, TTP and CR rates make this regimen an attractive alternative to MOPP/ABVD. However, the possibility of the development of second tumors is worrisome, although the relatively brief interval between the end of treatment and tumor detection may imply caution about the possible relationship.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalLeukemia and Lymphoma
Issue number3-4
Publication statusPublished - 1999


  • Advanced Hodgkin's disease
  • Chemotherapy
  • ChlVPP
  • Etoposide
  • Hybrid regimen

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: A study in 36 patients'. Together they form a unique fingerprint.

Cite this